Abstract: Disclosed is a non-aqueous electrolyte including an electrolyte salt and an electrolyte solvent, the non-aqueous electrolyte further including a compound containing both a carboxy group and a (meth)acrylic group, and a secondary battery including the non-aqueous electrolyte. The use of the compound containing both the carboxy group and the (meth)acrylic group as a component for an electrolyte significantly reduces the increase of battery thickness at high temperature storage.

Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.

Abstract: A washing machine which includes a lid assembly opening/closing a laundry entrance hole, wherein the lid assembly includes a lid frame and a lid inner coupled to an inside of the lid frame and having a hinge unit, is provided. The lid assembly may be easily assembled and maintain a secure coupling, thereby allowing for a reliable and stable washing machine. Further, the lid assembly may be easily opened or closed by the hinge unit, and this increases convenience.

Abstract: A process to crystallize uniform small particles of a compound of Formula (I) with narrow particle size distribution and excellent powder characteristics that facilitate the formulation process and optimal drug product performance, wherein the compound of Formula (I) is: wherein R1, R2, and R3 are as described herein.

Abstract: The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center, and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

Abstract: The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center, and all pharmaceutically acceptable salts, enantiomers and racemates, hydrates and solvates thereof and the use of these compounds for the treatment of inflammatory or allergic diseases of the respiratory tract such as COPD or asthma.

Abstract: A mobile terminal and a method of controlling the mobile terminal are disclosed. In the mobile terminal, at least one second application executable in a second operating system different from a first operating system can be searched and provided among at least one first application executable in the first operating system. Accordingly, it is possible to provide a user interface for efficiently managing applications so as to be appropriate for various operating systems.

Abstract: Compounds of Formula (I) wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Abstract: Provided is a crystalline form of the ethylenediamine salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid, processes for its preparation, pharmaceutical compositions comprising it, and methods of its use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.

Abstract: Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also provided.

Abstract: A mobile terminal includes a controller to establish a connection with a packet data network through a wireless communication unit. The controller selects one of a plurality of timer values that are respectively mapped to multiple applications for transmitting/receiving packet data through the connection based on a predetermined priority, operates a timer based on the selected timer value, and controls the connection based on the timer.

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract: Disclosed herein is a lithium secondary cell including 20 to 100 wt. % of lithium transition metal oxide represented by a formula of Li1+zNibMncMe1?(b+c)O2, relative to a total amount of a cathode active material, as well as an electrolyte consisting of a lithium salt and a non-aqueous solvent, wherein a first additive to form a protective film (that is, a solid electrolyte interface film: SEI film) over a surface of an anode active material and a second additive to form another SEI film over the surface of the anode active material while inactivating impurities contained in the cathode active material are included in the electrolyte.

Abstract: Disclosed is a non-aqueous electrolyte including an electrolyte salt and an electrolyte solvent, the non-aqueous electrolyte further including a compound containing both a carboxy group and a (meth)acrylic group, and a secondary battery including the non-aqueous electrolyte. The use of the compound containing both the carboxy group and the (meth)acrylic group as a component for an electrolyte significantly reduces the increase of battery thickness at high temperature storage.

Abstract: A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks.

Abstract: A fuel injecting control method during coasting of a vehicle, may include operating coasting mode when a coasting mode operation condition is satisfied, maintaining the coasting mode for a predetermined interval, injecting fuel according to engine speed, cutting fuel injecting when detected vehicle speed is equal to or more than a predetermined fuel cutting vehicle speed and less than a predetermined vehicle over speed, operating an assist brake when the detected vehicle speed is equal to or more than the predetermined vehicle over speed, and releasing the coasting mode when a releasing condition of the coasting mode is satisfied.

Abstract: A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. A process is also provided for preparing atazanavir bisulfate as Pattern C material. A novel form of atazanavir bisulfate is also provided which is Form E3 which is a highly crystalline triethanolate solvate of the bisulfate salt from ethanol.

Abstract: A washing machine which includes a lid assembly opening/closing a laundry entrance hole, wherein the lid assembly includes a lid frame and a lid inner coupled to an inside of the lid frame and having a hinge unit, is provided. The lid assembly may be easily assembled and maintain a secure coupling, thereby allowing for a reliable and stable washing machine. Further, the lid assembly may be easily opened or closed by the hinge unit, and this increases convenience.

Abstract: A process to crystallize uniform small particles of a compound of Formula (I) with narrow particle size distribution and excellent powder characteristics that facilitate the formulation process and optimal drug product performance, wherein the compound of Formula (I) is: wherein R1, R2, and R3 are as described herein.

Abstract: Disclosed herein is a lithium secondary cell including 20 to 100 wt. % of lithium transition metal oxide represented by a formula of Li1+zNibMncMe1?(b+c)O2, relative to a total amount of a cathode active material, as well as an electrolyte consisting of a lithium salt and a non-aqueous solvent, wherein a first additive to form a protective film (that is, a solid electrolyte interface film: SEI film) over a surface of an anode active material and a second additive to form another SEI film over the surface of the anode active material while inactivating impurities contained in the cathode active material are included in the electrolyte.